Skip to content

Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France

Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03624855
Enrollment
94
Registered
2018-08-10
Start date
2018-03-01
Completion date
2018-05-01
Last updated
2018-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone and Joint Infection

Brief summary

The aim of this study is to describe the bone or joint infection due to Pseudomonas aeruginosa in patients having implant.

Interventions

OTHERBone or joint infection due to Pseudomonas aeruginosa

Description of bone or joint infection on implant due to Pseudomonas aeruginosa

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years

Inclusion criteria

* patients having BJI on implant caused by Pseudomonas aeruginosa

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Description and rate of bone or joint infection on implant caused due to Pseudomonas aeruginosaOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)Description of the type of infection due to P. aeruginosa : patients and type of implant, profile of the bacterium, medical and chirurgical treatment, rate

Secondary

MeasureTime frameDescription
Rate of adverse events occurring under medical treatment against Pseudomonas aeruginosaOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)description of adverse events occurring under medical treatment against Pseudomonas aeruginosa in BJI
Rate of Treatment FailureOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026